Amyloid-β25-35 impairs memory and increases NO in the temporal cortex of rats

Neuroscience Research

Volumn 63, Issue 2, 2009, Pages 129-137

  Limón, I Daniel ^a,b,d   Díaz, Alfonso ^a,d   Mendieta, Liliana ^a   Chamorro, Germán ^b   Espinosa, Blanca ^c   Zenteno, Edgar ^e   Guevara, Jorge ^e  

^a BENEMÉRITA UNIVERSIDAD AUTÓNOMA DE PUEBLA   (Mexico)

^b INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^c INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^d Laboratorio de Enfermedades Neurodegenerativas Instituto Nacional de Neurología MVS   (Mexico)

^e UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Amyloid; Alzheimer's disease; Memory; Neurotoxicity; Nitric oxide; Nitric oxide synthase; Oxidative stress; Temporal cortex

Indexed keywords

3 NITROTYROSINE; AMYLOID BETA PROTEIN[25-35]; INDUCIBLE NITRIC OXIDE SYNTHASE; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; CONTROLLED STUDY; HIPPOCAMPUS; MALE; MEMORY DISORDER; NERVE CELL NECROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; RAT; SPATIAL MEMORY; TEMPORAL CORTEX;

AMYLOID BETA-PROTEIN; ANIMALS; BEHAVIOR, ANIMAL; GLIAL FIBRILLARY ACIDIC PROTEIN; MALE; MAZE LEARNING; MEMORY DISORDERS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE I; PEPTIDE FRAGMENTS; RATS; RATS, WISTAR; SILVER STAINING; SPACE PERCEPTION; TEMPORAL LOBE;

EID: 58149516815     PISSN: 01680102     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neures.2008.11.006     Document Type: Article

References (72)

1. Akama K.T., Albanese C., Pestell R.G., and Van Eldik L.J. Amyloid L-peptide stimulates nitric oxide production in astrocytes through an NFkappaB-dependent mechanism. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 5795-5800
2. Behl C. Alzheimer's disease and oxidative stress: implications for novel therapeutic approaches. Prog. Neurobiol. 57 (1999) 301-323
3. Braak H., and Braak E. Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol. 1 3 (1991) 213-216
4. Braak H., and Braak E. Argyrophilic grain disease: frequency of occurrence in different age categories and neuropathological diagnostic criteria. J. Neural Transm. 105 8-9 (1998) 801-819
5. Butterfield D.A., and Boyd-Kimball D. The critical role of methionine 35 in Alzheimer's amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity. Biochim. Biophys. Acta 1703 (2005) 149-156
6. Cheng G., Whitehead S.N., Hachinski V., and Cechetto D.F. Effects of pyrrolidine dithiocarbamate on beta-amyloid (25-35)-induced inflammatory responses and memory deficits in the rat. Neurobiol. Dis. 23 (2006) 140-151
7. Cutler R.G., Kelly J., Storie K., Pedersen W.A., Tammara A., Hatanpaa K., Troncoso J.C., and Mattson M.P. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. PNAS 101 (2004) 107
8. De la Monte S.M., Jhaveri A., Maron B.A., and Wands J.R. Nitric oxide synthase 3-mediated neurodegeneration after intracerebral gene delivery. J. Neuropathol. Exp. Neurol. 66 4 (2007) 272-283
9. De Olmos J.S., Beltramino C.A., and De Olmos De Lorenzo S. Use of an amino-cupric-silver technique for the detection of early and semiacute neuronal degeneration caused by neurotoxicants, hypoxia and physical trauma. Neurotoxicol. Teratol. 16 (1994) 545-561
10. Delobbette S., Privat A., and Maurice T. In vitro aggregation facilities betaamyloid peptide-(25-35)-induced amnesia in the rat. Eur. J. Pharmacol. 319 (1997) 1-4
11. Drake J., Link C.D., and Butterfield D.A. Oxidative stress precedes fibrillar deposition of Alzheimer's disease amyloid beta-peptide (1-42) in a transgenic Caenorhabditis elegans model. Neurobiol. Aging 24 (2003) 415-420
12. Duyckaerts C. Looking for the link between plaques and tangles. Neurobiol. Aging 25 6 (2004) 735-739
13. Garcia J.H., Liu K.F., and Ho K.L. Neuronal necrosis after middle cerebral artery occlusion in Wistar rats progress at different time intervals in the caudoputamen and the cortex. Stroke 26 (1995) 636-642
14. Good P.F., Werner P., Hsu A., Olanow C.W., and Perl D.P. Evidence of neuronal oxidative damage in Alzheimer's disease. Am. J. Pathol. 149 (1996) 21-28
15. Green L.C., Wagner D.A., Glogowski J., Skipper P.L., and Wishnok J.S. Analysis of nitrate, nitrite and [15N] nitrate in biological fluids. Anal. Biochem. 126 (1982) 131-138
16. Haas J., Storch-Hagenlocher B., Biessmann A., and Wildemann B. Inducible nitric oxide synthase and argininosuccinate synthetase: co-induction in brain tissue of patients with Alzheimer's dementia and following stimulation with b-amyloid 1-42 in vitro. Neurosci. Lett. 322 (2002) 121-125
17. Hayashi T., Shishido N., Nakayama K., Nunomura A., Smith M.A., Perry G., and Nakamura M. Lipid peroxidation and 4-hydroxy-2-nonenal formation by copper ion bound to amyloid-β peptide. Free Radic. Biol. Med. 43 (2007) 1552-1559
18. Heneka M.T., Wiesinger H., Dumitrescu-Ozimek L., Riederer P., Feinstein D.L., and Klockgether T. Neuronal and glial coexpression of argininosuccinate synthetase and inducible nitric oxide synthase in Alzheimer disease. J. Neuropathol. Exp. Neurol. 60 (2001) 906-916
19. Holscher C., Gengler S., Gault V.A., Harriott P., and Mallot H.A. Soluble beta-amyloid[25-35] reversibly impairs hippocampal synaptic plasticity and spatial learning. Eur. J. Pharmacol. 561 1-3 (2006) 85-90
20. Hu J., Akama K.T., Krafft G.A., Chromy B.A., and Van Eldik L.J. Amyloid-beta peptide activates cultured astrocytes: morphological alterations, cytokine induction and nitric oxide release. Brain Res. 785 (1998) 195-206
21. Hu J., and el-Fakahany E.E. beta-Amyloid 25-35 activates nitric oxide synthase in a neuronal clone. Neuroreport 4 6 (1993) 760-762
22. Kiyota Y., Miyamoto M., and Nagaoka A. Relationship between brain damage and memory impairment in rats exposed to transient forebrain ischemia. Brain Res. 538 2 (1991) 295-302
23. Kontush A., Berndt C., Weber W., Akopyan V., Artl S., Schippling S., and Beisiegel U. Amyloid-beta is an antioxidant for lipoproteins in cerebrospinal fluid and plasma. Free Radic. Biol. Med. 30 (2001) 119-128
24. Koppal T., Drake J., Yatin S., Jordan B., Varadarajan S., Bettenhausen L., and Butterfield D.A. Peroxynitrite-induced alterations in synaptosomal membrane proteins: insight into oxidative stress in Alzheimer's disease. J. Neurochem. 72 (1999) 310-317
25. Law A., Gauthier S., and Quirion R. Say NO to Alzheimer's disease: the putative links between nitric oxide and dementia of the Alzheimer's type. Brain Res. Rev. 35 (2001) 73-96
26. Lee H.G., Zhu X., Nunomura A., Perry G., and Smith M.A. Amyloid beta: the alternate hypothesis. Curr. Alzheimer Res. 3 (2006) 75-80
27. Lee J., Chan S.L., and Mattson M.P. Adverse effect of a presenilin-1 mutation in microglia results in enhanced nitric oxide and inflammatory cytokine responses to immune challenge in the brain. Neuromol. Med. 2 (2002) 29-45
28. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193 1 (1951) 265-275
29. Masliah E.J., Alford R.M., Mallory M., Mattson M.P., Yang D.L., and Mucke D.W. Amyloid protein precursor stimulates excitatory amino acid transport. Implications for roles in neuroprotection and pathogenesis. J. Biol. Chem. 273 (1998) 12548-12554
30. Matsuoka Y., Picciano M., La Francois J., and Duff K. Fibrillar β-amyloid Aevokes oxidative damage in a transgenic mouse model of Alzheimer's disease. Neuroscience 104 3 (2001) 609-613
31. Mattson M., Goodman Y., Luo H., Fu W., and Furakawa K. Activation of NF-KappaB protects hippocampal neurons against oxidative stress induce apoptosis: evidence for induction of manganese superoxide dismutase and suppression of peroxinitrite production and protein tyrosine nitration. J. Neurosci. Res. 49 (1997) 681-697
32. Mattson M.P., and Chan S.L. Neuronal and glial calcium signaling in Alzheimer's disease. Cell Calcium 34 4-5 (2003) 385-397
33. Mattson M.P. Pathways towards and away from Alzheimer's disease. Nature 430 7000 (2004) 631-639
34. Maurice T., Lockhart B.P., and Privat A. Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction. Brain Res. 706 2 (1996) 181-193
35. Meda L., Baron P., and Scarlato G. Glial activation in Alzheimer's disease: the role of Abeta and its associated proteins. Neurobiol. Aging 22 (2001) 885-893
36. Moncada S., and Bolaños J.P. Nitric oxide cell bioenergetics and neurodegeneration. J. Neurochem. 97 (2006) 1676-1689
37. Morris R. Development of a water-maze procedure for studying spatial learning in the rat. J. Neurosci. Methods 11 (1984) 47-60
38. Nakamura M., Shishido N., Nunomura A., Smith M.A., Perry G., Hayashi Y., Nakayama K., and Hayashi T. Three histidine residues of amyloid-β peptide control the redox activity of copper and iron. Biochemistry 46 (2007) 12737-12743
39. Norris P.J., Faull R.L., and Emson P.C. Neuronal nitric oxide synthase (nNOS) mRNA expression and NADPH-diaphorase staining in the frontal cortex, visual cortex and hippocampus of control and Alzheimer's disease brains. Mol. Brain Res. 41 (1996) 36-49
40. Nunomura A., Perry G., Pappolla M.A., et al. Neuronal oxidative stress precedes amyloid-beta deposition in Down syndrome. J. Neuropathol. Exp. Neurol. 59 (2000) 1011-1017
41. Nunomura A., Perry G., Aliev G., Hirai K., Takeda A., Balraj E.K., Jones P.K., Ghanbari H., Wataya T., Shimohama S., Chiba S., Atwood C.S., Petersen R.B., and Smith M.A. Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol. 60 8 (2001) 59-67
42. Nunomura A., Castellani R.J., Zhu X., Moreira P.I., Perry G., and Smith M.A. Involvement of oxidative stress in Alzheimer disease. J. Neuropathol. Exp. Neurol. 65 7 (2006) 631-641
43. Nunomura A., Moreira P.I., Lee H.G., Xhu X., Castellani R.J., Smith M.A., and Perry G. Neuronal death and survival under oxidative stress in Alzheimer and Parkinson diseases. CNS & Neurol. Disord.-Drug Targets 6 (2007) 411-423
44. Parks J.K., Smith T.S., Trimmer P.A., Bennett Jr. J.P., and Parker Jr. W.D. Neurotoxic Abeta peptides increase oxidative stress in vivo through NMDA-receptor and nitric-oxide-synthase mechanisms, and inhibit complex IV activity and induce a mitochondrial permeability transition in vitro. J. Neurochem. 76 (2001) 1050-1056
45. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates. 4th edition (1998), Academic Press, London, UK
46. Pérez-Severiano F., Salvatierra-Sanchez R., Rodriguez-Perez M., Cuevas-Martinez E.Y., Guevara J., Limón D., Maldonado P.D., Medina-Campos O.N., Pedraza-Chaverri J., and Santamaria A. S-Allylcysteine prevents amyloid-beta peptide-induced oxidative stress in rat hippocampus and ameliorates learning deficits. Eur. J. Pharmacol. 489 (2004) 197-202
47. Pike C.J., Walencewicz-Wasserman A.J., Kosmoski J., Cribbs D.H., Glabe C.G., and Cotman C.W. Structure-activity analyses of β-amyloid peptides: contributions of the β25-35 region to aggregation and neurotoxicity. J. Neurochem. 64 (1995) 253-265
48. Pratico D., Uryu K., Leight S., Trojanoswki J.Q., and Lee V.M. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J. Neurosci. 21 (2001) 4183-4187
49. Riepe M.W. Cholinergic treatment: what are the early neuropathological targets?. Eur. J. Neurol. 12 Suppl. 3 (2005) 3-9
50. Rodrigo J., Fernandez Vizarra P., Castro-Blanco S., Bentura M.L., Nieto M., Gómez-Isla T., Martínez-Murillo R., Martínez A., Serrano J., and Fernández A.P. Nitric oxide in the cerebral cortex of amyloid-precursor protein (SW) Tg2576 transgenic mice. Neuroscience 128 (2004) 73-89
51. Sayre L.M., Moreira P.I., Smith M.A., and Perry G. Metal ions and oxidative protein modification in neurological disease. Ann. Ist Super Sanità 41 2 (2005) 143-164
52. Sayre L.M., Perry G., and Smith M.A. Oxidative stress and neurotoxicity. Chem. Res. Toxicol. 21 (2008) 172-188
53. Schuessel K., Schäfer S., Bayer T.A., Czech C., Pradier L., Müller-Spahn F., Müller W.E., and Eckert A. Impaired Cu/Zn-SOD activity contributes to increased oxidative damage in APP transgenic mice. Neurobiol. Dis. 18 (2005) 89-99
54. Selkoe D.J. Amyloid beta-protein and the genetics of Alzheimer's disease. J. Biol. Chem. 271 31 (1996) 18295-18298 Review
55. Smith M.A., Richey Harris P.L., Sayre L.M., Beckman J.S., and Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J. Neurosci. 17 8 (1997) 2653-2657
56. Smith M.A., Rottkamp C.A., Nunomura A., Raina A.K., and Perry G. Oxidative stress in Alzheimer's disease. Biochim. Biophys. Acta 1502 (2000) 139-144
57. Sriram K., Benkovic S.A., Hebert M.A., Miller D.B., and O'Callaghan J.P. Induction of gp130-related cytokines and activation of JAK2/STAT3 pathway in astrocytes precedes up-regulation of glial fibrillary acidic protein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of neurodegeneration: key signaling pathway for astrogliosis in vivo?. J. Biol. Chem. 279 (2004) 19936-19947
58. Stepanichev M.Y., Onufriev M.V., Mitrokhina O.S., Moiseeva Y.V., Lazareva N.A., and Vktorov I.V. Neurochemical, behavioral, and neuromorphological effects of central administration of beta-amyloid peptide (25-35) in rat. Neurochemistry 17 (2000) 291-306
59. Stepanichev M.Y., Moiseeva Y.V., Lazareva N.A., Onufriev M.V., and Gulyaeva N.V. Single intracerebroventricular administration of amyloid-beta (25-35) peptide induces impairment in short-term rather than long-term memory in rats. Brain Res. Bull. 61 (2003) 197-205
60. Stepanichev M.Y., Zdobnova I.M., Zarubenko I.I., Moiseeva Y.V., Lazareva N.A., Onufriev M.V., and Gulyaeva N.V. Amyloid-β(25-35)-induced memory impairments correlated with cell loss in rat hippocampus. Physiol. Behav. 80 (2004) 247-655
61. Stepanichev M., Zdobnova I., Zarubenko I., Lazareva N., and Gulyaeva N.V. Differential effects of tumor necrosis factor-alpha co-administered with amyloid beta-peptide (25-35) on memory function and hippocampal damage in rat. Behav. Brain Res. 175 (2006) 352-361
62. Sultana R., Poon H.F., Cai J., Pierce W.M., Merchant M., Klein J.B., Markesbery W.R., and Butterfield D.A. Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach. Neurobiol. Dis. 22 (2006) 76-87
63. Sun M.K., and Alkon D.L. Impairment of hippocampal CA1 heterosynaptic transformation and spatial memory by β-amyloid25-35. J. Neurophysiol. 87 (2001) 2442-2449
64. Tan T., Paris T.D., Mori T., Suo Z., Crawford F., Mattson M.P., Flavell R.A., and Mullan M. Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation. Science 286 (1999) 2352-2355
65. Thal D.R., Schultz C., Dehghani F., Yamaguchi H., Braak H., and Braak E. Amyloid beta-protein (Abeta)-containing astrocytes are located preferentially near N-terminal-truncated Abeta deposits in the human entorhinal cortex. Acta Neuropathol. 100 6 (2000) 608-617
66. Thal D.R., Rüb U., Orantes M., and Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58 12 (2002) 1791-1800
67. Turner P.R., O'Connor K., Tate W.P., and Abraham W.C. Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog. Neurobiol. 70 (2003) 1-32
68. Velliquete R.A., O'Connor T., and Vassar R. Energy inhibition elevates β-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer's disease pathogenesis. J. Neurosci. 25 (2005) 10874-10883
69. Yamada K., and Nabeshima T. Animal models of Alzheimer's disease and evaluation of anti-dementia drugs. Pharmacol. Ther. 88 (2000) 93-113
70. Yamaguchi Y., and Kawashima S. Effects of amyloid-β-(25-35) on passive avoidance, radial-arm maze learning and choline acetyltransferase activity in the rat. Eur. J. Pharmacol. 412 (2001) 265-272
71. Yankner B.A. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron 16 5 (1996) 921-932
72. Zou K., Gong J.S., Yanagisawa K., and Michikawa M. A novel function of monomeric amyloid beta-protein serving as an antioxidant molecule against metal-induced oxidative damage. J. Neurosci. 22 (2002) 4833-4841